Barinthus Biotherapeutics (NASDAQ:BRNS) Releases Earnings Results, Beats Expectations By $0.23 EPS

Posted by Doug Madison on Nov 8th, 2024

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.23, RTT News reports. The company had revenue of $14.97 million for the quarter. During the same period last year, the firm earned ($0.37) earnings per share.

Barinthus Biotherapeutics Stock Performance

Shares of NASDAQ:BRNS traded down $0.04 on Friday, reaching $1.43. 24,844 shares of the company’s stock were exchanged, compared to its average volume of 23,597. Barinthus Biotherapeutics has a twelve month low of $1.11 and a twelve month high of $4.16. The company has a fifty day moving average of $1.29 and a 200-day moving average of $1.58.

Wall Street Analysts Forecast Growth

BRNS has been the subject of a number of research analyst reports. Alliance Global Partners reduced their price objective on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Barinthus Biotherapeutics in a research note on Thursday, September 26th.

Read Our Latest Stock Report on Barinthus Biotherapeutics

Barinthus Biotherapeutics Company Profile

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.